Vincent Guilamo-Ramos, Marco Thimm-Kaiser, Adam Benzekri, Daniel E. Dawes
{"title":"Overcoming zero-sum thinking to advance US population health","authors":"Vincent Guilamo-Ramos, Marco Thimm-Kaiser, Adam Benzekri, Daniel E. Dawes","doi":"10.1038/s41591-025-03907-0","DOIUrl":null,"url":null,"abstract":"<p>There is broad consensus that the US healthcare system is failing. Policy initiatives to reduce costs and improve healthcare outcomes have been longstanding priorities across presidential administrations, but there has been limited success. The USA continues to achieve worse outcomes than those of comparable high-income countries while spending more on healthcare<sup>1</sup>.</p><p>One important factor preventing reforms is zero-sum thinking about health inequities: the belief that investing to improve the health of population segments with the worst outcomes comes at the expense of those with better baseline health<sup>2</sup>. Here we challenge the zero-sum thinking that denies the broader, population-level benefits of eliminating health inequities. First, we show how health inequities harm the whole US population, not just marginalized groups, highlighting how reducing inequities benefits everyone. Second, we identify four common fallacies in healthcare-related zero-sum thinking and counter each. Finally, we argue the importance of overcoming zero-sum thinking for advancing substantive healthcare reforms.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"9 1","pages":""},"PeriodicalIF":50.0000,"publicationDate":"2025-08-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03907-0","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
There is broad consensus that the US healthcare system is failing. Policy initiatives to reduce costs and improve healthcare outcomes have been longstanding priorities across presidential administrations, but there has been limited success. The USA continues to achieve worse outcomes than those of comparable high-income countries while spending more on healthcare1.
One important factor preventing reforms is zero-sum thinking about health inequities: the belief that investing to improve the health of population segments with the worst outcomes comes at the expense of those with better baseline health2. Here we challenge the zero-sum thinking that denies the broader, population-level benefits of eliminating health inequities. First, we show how health inequities harm the whole US population, not just marginalized groups, highlighting how reducing inequities benefits everyone. Second, we identify four common fallacies in healthcare-related zero-sum thinking and counter each. Finally, we argue the importance of overcoming zero-sum thinking for advancing substantive healthcare reforms.
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.